JP2021527107A5 - - Google Patents

Info

Publication number
JP2021527107A5
JP2021527107A5 JP2020569836A JP2020569836A JP2021527107A5 JP 2021527107 A5 JP2021527107 A5 JP 2021527107A5 JP 2020569836 A JP2020569836 A JP 2020569836A JP 2020569836 A JP2020569836 A JP 2020569836A JP 2021527107 A5 JP2021527107 A5 JP 2021527107A5
Authority
JP
Japan
Prior art keywords
chi
inhibitor
antibody
agent according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/065617 external-priority patent/WO2019238893A1/en
Publication of JP2021527107A publication Critical patent/JP2021527107A/ja
Publication of JP2021527107A5 publication Critical patent/JP2021527107A5/ja
Pending legal-status Critical Current

Links

JP2020569836A 2018-06-14 2019-06-13 インターロイキン−1の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療 Pending JP2021527107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305729 2018-06-14
EP18305729.8 2018-06-14
PCT/EP2019/065617 WO2019238893A1 (en) 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1

Publications (2)

Publication Number Publication Date
JP2021527107A JP2021527107A (ja) 2021-10-11
JP2021527107A5 true JP2021527107A5 (enExample) 2022-06-17

Family

ID=62791692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569836A Pending JP2021527107A (ja) 2018-06-14 2019-06-13 インターロイキン−1の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療

Country Status (5)

Country Link
US (1) US20210115131A1 (enExample)
EP (1) EP3807313A1 (enExample)
JP (1) JP2021527107A (enExample)
CN (1) CN112236453A (enExample)
WO (1) WO2019238893A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素-1受体拮抗剂治疗非典型性肺炎的用途
ES2677944T3 (es) * 2009-11-25 2018-08-07 Hologic Inc. Detección de infección intraamniótica

Similar Documents

Publication Publication Date Title
Jacobs et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor
Ferretti et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.
JP5337055B2 (ja) 免疫性障害の処置のための組合せ治療
HRP20100014T1 (hr) Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti
JP2017501680A5 (enExample)
Sadura-Sieklucka et al. Effects of whole body cryotherapy in patients with rheumatoid arthritis considering immune parameters
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
Lin et al. Expressions of chemokines and their receptors in the brain after heat stroke-induced cortical damage
CN107405403A (zh) 用于治疗纤维化的塞尼克韦罗
Bhatt et al. Promising pharmacologic innovations in treating pulmonary fibrosis
Şahin et al. Reduced cerebrospinal fluid levels of interleukin-10 in children with febrile seizures
Wang et al. Renin-dependent hypertension in mice requires the NLRP3-inflammasome
Guo et al. Thalidomide alleviates postoperative pain and spatial memory deficit in aged rats
JP2019502739A (ja) レイノー現象および免疫異常を患う患者における全身性強皮症の予防治療に使用するためのp2y12受容体を阻害する物質
Han et al. The first case series of cryopyrin-associated periodic syndrome in Korea
Edye et al. Epilepsy and the inflammasome: targeting inflammation as a novel therapeutic strategy for seizure disorders
Man et al. The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study
Nemeth et al. Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors
Di Domenico et al. Xolair in asthma therapy: an overview
CN112533675A (zh) 通过递送抗OSMRβ抗体治疗皮肤疾病或病症
CN115942933A (zh) 用于治疗气道疾病的(1r,3s)-3-((5-氰基-4-苯基噻唑-2-基)氨基甲酰基)环戊烷-1-羧酸及其衍生物
US20260078181A1 (en) Trem-2 agonists for the treatment of marfan syndrome
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
EP4192452B1 (en) Compositions comprising carboxyamidotriazole orotate for use in preventing or treating sars-cov-2 infection
ES3049513T3 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation